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Background: Great saphenous vein (GSV) incompetence is the most common cause of superficial venous insufficiency.
Radiofrequency catheter ablation (RFA) is superior to conventional ligation and stripping, and endovenous laser
treatment (EVL) has emerged as an effective alternative to RFA. This randomized study evaluated RFA and EVL for
superficial venous insufficiency due to GSV incompetence and compared early and 1-year results.
Methods: Between June 2006 and May 2008, patients with symptomatic primary venous insufficiency due to GSV
incompetence were randomized to RFA or EVL. Patients with bilateral disease were randomized for treatment of the first
leg and received the alternative method on the other. Pretreatment examination included a leg assessment using the
Venous Clinical Severity Score (VCSS) and CEAP classification. Patients completed the Chronic Venous Insufficiency
Questionnaire 2 (CIVIQ2). RFA was performed with the ClosurePlus system (VNUSMedical Technologies, Sunnyvale,
Calif). EVL was performed with the EVLT system (AngioDynamics Inc, Queensbury, NY). Early (1-week and 1-month)
postoperative results of pain, bruising, erythema, and hematoma were recorded. Duplex ultrasound (DU) imaging was
used at 1 week and 1 year to evaluate vein status. VCSS scores and CEAP clinical class were recorded at each postoperative
visit, and quality of life (QOL) using CIVIQ2 was assessed at 1 month and 1 year.
Results: The study enrolled 118 patients (141 limbs): 46 (39%) were randomized to RFA and 48 (40%) to EVL, and 24
(20%) had bilateral GSV incompetence. At 1 week, one patient in the RFA group had an open GSV and was deemed a
failure. More bruising occurred in the EVL group (P .01) at 1 week, but at 1 month, there was no difference in bruising
between groups. At 1 year, DU imaging showed evidence of recanalization with reflux in 11 RFA and 2 EVL patients
(P  .002). The mean VCSS score change from baseline to 1 week postprocedure was higher for RFA than EVL (P 
.002), but there was no difference between groups at 1 month (P  .07) and 1 year (P  .9). Overall QOL mean score
improved over time for all patients (P < .001). CEAP clinical class scores of >3 were recorded in 21 RFA (44%) and 24
EVL patients (44%) pretreatment, but at 1-year, 9 RFA (19%) and 12 EVL patients (24%) had scores of >3 (P < .001).
This represented a significant improvement in all patients compared with baseline.
Conclusion: Both methods of endovenous ablation effectively reduce symptoms of superficial venous insufficiency. EVL is
associated with greater bruising and discomfort in the perioperative period but may provide a more secure closure over
the long-term than RFA. (J Vasc Surg 2010;52:645-50.)Endoluminal thermal ablation is widely recognized to
be effective in treating symptomatic lower extremity super-
ficial venous reflux, and it has advantages over ligation and
stripping that have been demonstrated in randomized clin-
ical trials comparing the procedures.1,2 Thermal ablation
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Vascular Surgery.doi:10.1016/j.jvs.2010.04.030patients experienced less postoperative discomfort, re-
turned to normal activity sooner, reported fewer complica-
tions at 3 weeks, and had better improvement in quality of
life (QOL) scores.1-3
Since the introduction of radiofrequency ablation
(RFA) into the venous therapeutic armamentarium in 1998
to 1999, followed by endovenous laser treatment (EVL) in
2002, the field has grown rapidly. A number of different
laser systems and two generations of radiofrequency cath-
eters are available. Both techniques report successful oblit-
eration of the great saphenous vein (GSV), small saphenous
vein, saphenofemoral junction (SFJ) branches, and perfo-
rators.4 Studies of the individual techniques have not
shown differences in patient safety, and overall success rates
appear similar.2,5 However, there may be differences in
comfort, degree of bruising, and completeness of vein
obliteration.4,6 This randomized study evaluated object-
ive outcomes of QOL, Venous Clinical Severity Scores
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pain, bruising, and paresthesia, and efficacy outcomes of
vein obliteration at 1 week and 1 year in patients undergo-
ing endoluminal saphenous vein ablation with RFA or
EVL.
MATERIALS AND METHODS
The Institutional Review Board approved the study
protocol, and all patients signed an informed consent.
Patients. Between June 2006 and May 2008, patients
presenting with symptomatic primary venous insufficiency
due to GSV incompetence were evaluated for inclusion
in this study. The study excluded patients with post-
thrombotic venous disease and patients requiring long-
term therapeutic anticoagulation.
Study protocol. Patients who were enrolled in the
study underwent pretreatment duplex ultrasound (DU)
imaging in the noninvasive vascular laboratory to record
reflux times, vein diameters, presence or absence of acute
thrombosis or chronic obstruction, areas of large sinuses,
and varicosities of the great and small saphenous veins. A
pretreatment office examination by the physician and clin-
ical research nurse included a complete history and physical
examination, leg assessment using the VCSS,7 and a CEAP
clinical classification.8 Patients completed the Chronic Ve-
nous Insufficiency Questionnaire 2 (CIVIQ2).9
Patients were randomized to the RFA or EVL study
group in a 1:1 fashion, with the randomization envelope
placed in the patient’s medical record. If a patient random-
ized to one treatment group required treatment of the
contralateral leg at a later date, the contralateral leg was
treated with the alternative procedure. Because it is our
practice to performmicrophlebectomies at the time of GSV
ablation, patients who required excision of branch varicos-
ities underwent microphlebectomy and GSV ablation as
one procedure.
Study outcomes included (1) vein obliteration at 1
week and 1 year as measured by DU imaging, (2) compli-
cations at 1 week, 1 month, and 1 year, and (3) QOL at 1
month and 1 year.
Treatment details. RFA was performed with the Clo-
surePLUS System (VNUSMedical Technologies, San Jose,
Calif), and EVL was performed with the EVLT 810-nm
diode laser fiber system (AngioDynamics Inc, Queensbury,
NY). GSV access was achieved with ultrasound guidance
under local anesthesia. The RFA and laser catheters were
positioned just distal to the inferior epigastric vein. Tume-
scent anesthesia (a combination of 400 mL of 0.9% chilled
sodium chloride and 100 mL of 1% lidocaine, with or
without epinephrine, depending on the patient’s age) was
administered under ultrasound guidance using a 20-gauge
needle infused with a Klein pump (HK Surgical Inc, San
Clemente, Calif). Technical details of each procedure were
recorded, including but not limited to, indications, quan-
tity of tumescent anesthesia, catheter withdrawal time and
energy parameters, length of treatment and anatomic land-
marks, perioperative ultrasound findings regarding obliter-
ation, and number and location of phlebectomies.The RFA ClosurePLUS 6 catheter was withdrawn at 2
cm/min for the first minute of treatment and thereafter at
approximately 3 cm/min at temperatures of 85° to 90° C.
EVL patients were treated at 14 W continuous energy, and
the fiber was withdrawn at 1 mm/s for the first 10 cm and
then at 2.5 to 4.0 mm/s for the remaining distance of the
treated vein.
After the procedure, legs were wrapped with elastic
compression bandages for 72 hours. Patients were encour-
aged to ambulate and to continue ongoing compression
therapy with 20 to 30mmHg knee-high gradient compres-
sion hose for at least 2 weeks.
Follow-up. Patients returned at 1 week, 1 month, and
1 year for follow-up. DU imaging was performed at 1 week
and 1 year to evaluate vein status. Limbs were examined for
pain (visual analog scale), bruising, erythema, and hema-
toma at each postoperative visit. CEAP clinical class and
VCSS scores were recorded. Bruising was assessed using a
scale from 0 (no visible bruising) to 5 (excessive bruising).
Because these measures are specific to the leg, they are
reported by limb, not by patient. The patients with bilateral
disease therefore contributed data to both RFA and EVL
outcomes.
QOL was assessed at 1 month and 1 year after treat-
ment using the standardized global score from the
CIVIQ2. This score ranges from 0 to 100, where 100
represents the highest QOL. The CIVIQ2 has excellent
test-retest reliability (Pearson correlation coefficients
0.94) and also correlates significantly with clinical out-
comes.9
Bilateral patients. Patients with bilateral disease re-
ceived their randomized treatment on the first leg and the
alternate treatment on the second leg. Before the second
procedure, follow-up data were collected and reported for
the respective treatment group (first leg). Once the second
procedure was completed, however, the QOL data were
reported separately for the bilateral group.
Statistical methods. Baseline characteristics of the
sample were compared using analysis of variance, t tests,
and the Fisher 2 tests. Differences in outcomes among the
treatment groups and the effects of treatment over time
were evaluated with generalized linear models and repeated
measures analysis of variance. All analyses were performed
with SAS 9.1.2 software (SAS Institute, Cary, NC).
RESULTS
The study enrolled 118 patients (141 limbs), of which
46 (39%) were randomized to treatment with RFA and 48
(40%) to EVL, and 24 (20%) had bilateral GSV incompe-
tence. The bilateral group was older than the RFA or EVL
groups (P  .03) and had higher systolic blood pressure
(P .04). There were no other differences in comorbidities
or demographics among the groups (Table I; P  .2).
Results of the patients with bilateral disease are included in
the Tables and separately identified where appropriate.
All veins were closed at 1 week after the procedure. At
1 year, 12 patients (20 limbs) were lost to follow-up,
equally distributed between treatment groups. There was
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painful erythema was reported in two RFA and five EVL
patients. At 1 month, there was no difference in bruising
among groups. The mean number of microphlebectomies
was 5.5 3.1 (range, 1-13) in RFA patients and 6.5 3.3
(range, 1-15) in the EVL cohort; in the EVL group, 79% of
patients had more than three microphlebectomies com-
pared with 63% of RFA patients.
Mean (SD) J/cm measurements for the 73 EVL pa-
tients were 92 (14.2; range 63-135). No thrombus ex-
tended proximally from the SFJ on follow-up DU exami-
nation; however, a peroneal deep vein thrombosis
developed in 1 EVL patient at 1 week. This patient, who
had a history of tobacco use, superficial phlebitis, and
stroke, received anticoagulation (enoxaparin, followed by
warfarin) for 6 weeks, after which there was no further
evidence of deep vein thrombosis.
DU imaging at the 1-year follow-up showed evidence
of recanalization, with reflux in 11 RFA and 2 EVL patients
(13 limbs) involving one or more segments (P  .002;
Table II). However, analysis of the 1-year VCSS and QOL
data suggested clinical improvement from baseline in most
of these patients, despite the anatomic failure of treatment.
The mean VCSS score change from baseline to 1 week after
the procedure was greater for RFA than EVL (P  .002),
but no difference among the treatment groups existed at 1
month (P  .07) or at 1 year (P  .9; Table III). QOL
scores for the bilateral group were initially higher than for
the EVL or RFA groups, but were similar over time (P .5;
Table IV). The meanQOL score improved over time for all
Table I. Patient demographics
Variable EVL RFA Bilateral
Female, No. (%) 36 (75) 29 (63) 20 (83)
Male (%) 12 (25) 17 (37) 4 (17)
Age (mean) 49 46 54a
Systolic BP, mean mm Hg 118 119 126a
BMI, mean kg/m2 28 28 31
Hypertension, No. (%) 16 (33) 10 (22) 5 (21)
Dyslipidemia, No. (%) 7 (15) 9 (20) 4 (17)
Smoking, No. (%) 5 (10) 4 (9) 2 (8)
Diabetes, No. (%) 1(2) 2 (4) 2 (8)
BMI, Body mass index; BP, blood pressure; EVL, endovenous laser; RFA,
radiofrequency ablation.
aStatistically significant.
Table II. Recanalized vein diameter at 1 year in
treatment failures
Diameter reduction EVL (n  2) RFA (n  11)
Unchanged 0 3
25% 0 2
33% 1 1
50% 1 5
EVL, Endovenous laser; RFA, radiofrequency ablation.patients (P  .001).Before treatment, 21 RFA patients (44%) and 24 EVL
patients (49%) had a clinical class of CEAP score of3. By
the 1-year follow-up visit, 9 of the RFA patients (19%) and
12 of the EVL patients (24%) had scores of3 (P .001).
There was no difference in CEAP clinical class improve-
ment between treatment groups.
The mean VCSS score at baseline was higher in the
RFA treatment group (6.4  2.2) than in the EVL group
(5.9  2.5; P  .001). Subsequent comparisons between
treatment groups were adjusted for the baseline VCSS
score. After adjustment, the change in VCSS score at 1
week after the procedure was significantly greater for the
RFA group than for the EVL group (P  .002). By 1
month, the differences in VCSS score marginally favored
the RFA group (P  .07), and by 1 year, there was no
difference between groups (P  .9; Fig 1; Table III).
The CIVIQ2 global index scores significantly improved
over time for all patients, regardless of treatment (P .001;
Table IV; Fig 2). The change in CIVIQ2 score over time by
treatment group was adjusted by age, body mass index
(BMI), gender, and race; however, only age modified the
change in CIVIQ2 score (P  .004). A significant differ-
ence in the change from baseline to 1 month was noted
among the bilateral patients compared with the other two
groups (P .018), but there was no difference between the
RFA and EVL groups (P  .13). After 1 month, there was
no significant difference among the three groups (P .24;
Table IV). All patients enjoyed improved QOL, regardless
of age (P  .001; Fig 3).
All patients, regardless of procedure type, demon-
strated a significant decrease (P  .001) in vein diameter
Table III. Venous Clinical Severity Score (VCSS) mean
score change over time by treatment group (successes
only)
Treatment No.
Mean VCSS score changea
1 week 1 month 1 year
EVL 70 0.86 3.82 4.69
RFA 59 1.84 4.21 4.90
P .0006 .11 .5
EVL, Endovenous laser; RFA, radiofrequency ablation.
aAdjusted for baseline VCSS score.
Table IV. Quality of life (QOL) scores over time by type
of treatment (successes only)
Treatment
QOL scores at follow-up time points
PaBaseline (SD) Month (SD) Year (SD)
Bilateral 75.2 (22.9) 88.7 (11.1) 95.5 (4.8) .0016
EVL 63.8 (22.2) 87.5 (12.0) 94.1 (7.6) .001
RFA 66.5 (16.9) 89.3 (10.3) 93.8 (6.3) .001
EVL, Endovenous laser; RFA, radiofrequency ablation.
aBaseline to 1 year.from baseline to 1 year as measured near the SFJ, thigh,
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patients showed greater reduction in vein diameter at the
SFJ (P  .021), knee (P  .019), and calf (P  .022) than
RFA patients (Table V). The initial vein diameters of pa-
tients in the failure group were larger at the SFJ (P .033)
and thigh (P .007; Table VI) than in successfully treated
patients. A vein diameter reduction of at least 25% was
demonstrated at 1 year in 10 of 13 (77%) patients in the
treatment failure group (Table II).
DISCUSSION
The goal of catheter-based endovenous ablation is the
comfortable and durable occlusion of the treated vein to
Fig 1. Graph illustrates the change in mean Venous Clinical
Severity Score (VCSS) scores over time in patients undergoing
endovenous laser (EVL) ablation and radiofrequency ablation
(RFA).
Fig 2. Despite higher recanalization with radiofrequency abla-
tion (RFA) compared with endovenous laser (EVL) ablation, all
patients enjoyed improved quality of life according to Chronic
Venous Insufficiency Questionnaire (CVIQ) at 1 year.eliminate pathologic reflux. This study compared patient-related outcomes of pain, bruising, paresthesias, and QOL
and efficacy outcomes of luminal obliteration between two
techniques of percutaneous endoluminal vein ablation. The
Fig 3. Age older or younger than 60 years was not a determinant
of outcome for quality of life according to the Chronic Venous
Insufficiency Questionnaire (CVIQ).
Table V. Mean vein diameter change (mm) by treatment
group (successes only)
Segment Time
EVL
(70 limbs)
RFA
(59 limbs) Pa
SFJ Baseline 7.7 7.6 .021
1 year 1.4 2.8
Thigh Baseline 5.7 5.5 .064
1 year 0.3 0.8
Knee Baseline 5.2 5.0 .019
1 year 0.4 1.5
Calf Baseline 3.6 3.4 .022
1 year 1.3 2.0
EVL, Endovenous laser; RFA, radiofrequency ablation; SFJ, saphenofemo-
ral junction.
aP compares change in vein size over time.
Table VI. Mean vein diameter change (mm) by
treatment failures and successes
Segment Time
Failure
(13 limbs)
Success
(129 limbs) Pa
SFJ junction Baseline 9.6 7.7 .033
1 year 7.7 2.0
Thigh Baseline 6.8 5.6 .007
1 year 4.5 0.5
Knee Baseline 7.1 5.1 0.17
1 year 4.2 0.8
Calf Baseline 4.4 3.5 0.6
1 year 2.5 1.6
EVL, Endovenous laser; RFA, radiofrequency ablation; SFJ, saphenofemo-
ral junction.
aP compares change in vein size over time.mechanisms of luminal ablation are fundamentally different
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has probes that contact the vein wall. When activated,
radiofrequency energy is delivered to the vein wall and
converted to heat. The heat produces tissue damage in the
form of endothelial denudation, denaturation of proteins
within the vein wall (collagen), stimulation of inflamma-
tion, vein shrinkage, and thrombosis.
With EVL treatment, laser wavelengths of 810 to 1064
nm are absorbed by the hemoglobin of red blood cells,
which leads to the formation of steam bubbles that produce
convective heat transfer to the vein wall. The heat damages
endothelium and subendothelial collagen, causing shrink-
age of the vein wall, inflammation, thrombosis, and subse-
quent fibrosis. If the tip of the laser catheter is in contact
with the vein wall, high-energy absorption by small vol-
umes of tissue can lead to tissue vaporization, resulting in
vein perforation. Blood leaking from these perforations
leads to ecchymoses.
Our findings support the notion that perioperative
bruising and discomfort are greater with EVL: 79% of EVL
patients had three or more microphlebectomies compared
with 63% in the RFA group, raising the possibility of
technique bias because the microphlebectomies could pos-
sibly have contributed to bruising and discomfort. We have
adopted the approach of a single-setting treatment of
branch varices with endoluminal ablation rather than stag-
ing the procedures. This approach safely and effectively
eliminates reflux and also provides the functional and cos-
metic improvement with one procedure. The number of
phlebectomies did not influence QOL in either treatment
group (P  .2).
Anatomic failure at 1 year was higher with RFA vs EVL
(P  .002). Failure was significantly correlated with vein
diameter. Patients with recanalization at 1 year had signif-
icantly larger baseline diameters at the SFJ and thigh. This
observation suggests that an inadequate amount of energy
was delivered to the vein wall in the larger veins. Although
it occurred predominantly with RFA in this study, the
principle of inadequate energy delivery to the vein wall has
been objectively assessed with EVL. Proebstle et al10 ana-
lyzed the linear endovenous energy density delivered to the
vein wall vs the proximal GSV diameter and showed that
low linear endovenous energy density values are associated
with recanalization and that veins with larger diameters
required the delivery of greater amounts of energy for
durable occlusion.
An interesting finding was that anatomic failure at 1
year did not correlate with QOL; in fact, there was no
difference in QOL between treatment groups. This may be
partly explained by the reduction in vein diameter, which
occurred in nearly all treated patients, as well as by the
benefits they may have received from the excision of branch
varicosities and perhaps better compliance with compres-
sion. Although these are observations at 1 year, this repre-
sents relatively short follow-up.
Early recanalization of the GSV after endothermal ab-
lation has been associated with excess BMI, large vein
diameter, anticoagulation, insufficient laser energy, RFAtreatment temperature 85°C, and RFA pullback speed
3 cm/min.11,12-14 It is not clear at what BMI threshold
recanalization risk begins; however, the larger the leg,
the more difficult it is to achieve adequate perioperative
vein compression with tumescent anesthesia, compression
wraps, and stockings. Other authors have suggested that
BMI30 kg/m2 is a risk factor for recanalization.13 In our
study, the BMIwas30 kg/m2 in 6 of 13 patients (46%) in
the anatomic failure group compared with 32 of the 105
patients (30%) who had successful outcomes. There was no
significant difference in QOL over time due to BMI (P 
.5). In the RFA group of ultrasound-documented failures,
catheter pullback speeds 3.5 cm/min were used in three
patients; however, these patients all had had compensatory
treatment temperatures of 90°C rather than the standard
85°C. No patient in the treatment failure group was receiv-
ing anticoagulation.
Improved QOL was observed for all patients, regard-
less of age (P  .001). Fig 3 shows the QOL over time for
patients aged 60 years vs patients 60, illustrating no
significant difference in overall QOL improvement (P 
.2). This would suggest that age should not disqualify an
individual from being offered the benefit of endovenous
thermal ablation for symptomatic superficial venous reflux.
An interesting facet of this study was the opportunity to
compare the two procedures in the same patient. The
bilateral group comprised 24 patients who required treat-
ment in both legs. There was a subjective preference for
RFA based on early postoperative results (1 month). At 1
year, however, 62% of the bilateral patients stated no pref-
erence.
The challenge remains to develop an endothermal sys-
tem that results in secure long-term obliteration of the
saphenous vein with minimal perioperative pain and bruis-
ing. With the lower wavelength lasers, such as the 810-nm
system used in our study, the photons target the hemoglo-
bin within the vein (hemoglobin-specific laser wavelength),
resulting in steam bubbles from boiling blood, which can
be curiously audible. Together with the laser tip and narrow
beam contact with the vein wall, vessel wall perforations
and asymmetric ablations have been demonstrated with
optical coherence tomography.15 In comparison, similar
quantitative analyses of effects of RFA in the ex vivo model
show symmetrical, circumferential, thorough destruction
of intima and media, without perforations, and collagen
denaturation is more pronounced and reproducible com-
pared with the bare-tipped laser fiber. When attempting to
develop the ideal endothermal saphenous ablation system
(permanent, secure closure without discomfort), it makes
sense to minimize injury to the vein adventitia, where
sympathetic nerve pain fibers travel and many of the fibro-
blasts necessary for lumen fibrosis originate.16
Higher laser wavelengths that are water-specific are
now available for targeting the water content of the vein
wall and may avoid steam bubbles from boiling blood
associated with the lower wavelength lasers. The 1320-nm
water-specific laser wavelength reduced postoperative
bruising and pain compared with the 940-nm hemoglobin-
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1470-nm system with an even higher affinity for water
absorption showed successful vein ablation with lower en-
ergy densities, and perioperative comfort was similar to
RFA.18 A radial-emitting laser fiber design may also have a
future role in achieving the ideal system because the light is
distributed circumferentially 360° for more symmetrical
treatment of the vein wall.
The second-generation RFA catheter ClosureFAST
(VNUS Medical Technologies) has been available since
2008. It uses higher operating temperatures (120°C) than
the first-generation ClosurePLUS bipolar catheter (85° to
90°C) used in our study. The newer catheter conducts heat
evenly and directly to the vein wall through a 7-cm-long
heating coil at the end of the catheter. Compared with
980-nm laser ablation, a recent randomized trial showed
the ClosureFAST device resulted in a more comfortable
recovery at 48 hours and at 1 and 2 weeks.19 Durability of
obliteration was not addressed in the ClosureFAST study.
Unfortunately, ClosureFAST was compared with the early-
generation EVL and not the 1320-nm water-specific laser
wavelength that is now available.
CONCLUSION
RFA and EVL both effectively reduce superficial ve-
nous insufficiency from incompetent GSVs. In this study,
EVL was associated with more bruising in the periproce-
dural period butmay provide amore secure closure over the
long-term compared with the RFA ClosurePLUS catheter.
Age should not disqualify a patient for endovenous thermal
ablation for superficial venous reflux. However, larger veins
may require more energy delivery for successful oblitera-
tion.
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